Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
PubWeight™: 0.75‹?›
Published in Mol Cancer on June 07, 2017
Author Affiliations
1: Department of Neurosurgery & Shenzhen Key Laboratory of Neurosurgery, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, China.
2: Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.
3: Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China.
4: College of Clinical Medicine, Anhui Medical University, Hefei, 230032, China.
5: Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, China. tony.to@polyu.edu.hk.
6: Department of Neurosurgery & Shenzhen Key Laboratory of Neurosurgery, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, China. wpli@szu.edu.cn.
Articles by these authors ⇆